CytoDyn

293 articles with CytoDyn

• CytoDyn Announces Investment Community Conference Call

  11/18/2015

• CytoDyn Injects First Patient In Its Current Phase III Study

  10/22/2015

• CytoDyn Files An IND And Full Protocol For Phase II Study In GvHD

  10/20/2015

• CytoDyn Release: HIV Patients Successfully Reach One Year Of Virologic Suppression In PRO 140 Monotherapy Study

  9/21/2015

• CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial

  8/18/2015

• CytoDyn Initiates First Clinical Site For Phase III Trial Of PRO 140

  8/6/2015

• CytoDyn Completes Qualification Of PRO 140 Material For Phase III

  7/29/2015

• CytoDyn Release: Evidence Of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months

  7/15/2015

• CytoDyn To Expand Clinical Applications For PRO 140 Beyond Therapy For HIV

  6/24/2015

• CytoDyn Cleared By FDA To Start Phase III Of First Injectable Antibody For HIV

  6/9/2015

• CytoDyn Submits Phase 3 Protocol To FDA After Agreement On Protocol Synopsis

  5/4/2015

• CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks Of Monotherapy - Many HIV Patients In Extension Study With Some Approaching 6 Months

  2/3/2015

• CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program

  11/25/2014

• CytoDyn Announces Investment Community Call To Discuss Results From Its Treatment Substitution Clinical Trial In Patients With HIV

  10/13/2014

• CytoDyn Announces 100% Success With PRO 140 In Four-Week Monotherapy Clinical Trial

  10/13/2014

• CytoDyn Appoints Carl Dockery To Board Of Directors

  10/2/2014

• CytoDyn Announces Webcast For Annual Shareholder Meeting

  8/18/2014

• CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV

  7/31/2014

• CytoDyn Announces Investment Community Call To Discuss Interim Results From Its Treatment Substitution Study In Patients With HIV

  7/31/2014

• CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy

  5/15/2014